Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3355 crossover pharmacodynamic study in GERD patients with incomplete response to PPI
2006-004501-25Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lesogaberan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of transient lower esophageal sphincter relaxations. Started Nov 2006; status: completed.
02
Drugs
lesogaberan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2006-004501-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004501-25.